SIMC yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SIMC pulled ahead of the other in Year 1
Combined, SIMC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SIMC + ABBV for your $10,000?
Simclar, Inc., together with its subsidiaries, operates as a contract manufacturer of electronic and electro-mechanical products in the United States and Mexico. Its custom-designed products include complex printed circuit boards (PCBs), finished products, subassemblies, molded and nonmolded cable assemblies, wire harnesses, injection molded, and electronic assembly products. The PCBs produced by the company comprise pin-through-hole assemblies, low and medium volume surface mount technology assemblies, and mixed technology PCBs, including multilayer PCBs; and cable and harness assemblies consist of multiconductor, ribbon, coaxial cable, and discrete wire harness assemblies. The company also provides contract manufacturing services, which involves the manufacture of complete finished assemblies with all sheet metal, power supplies, fans, and PCBs, as well as complete sub-assemblies for integration into original equipment manufactures (OEMs) finished products, such as speaker and lock-key assemblies, and diode assemblies. In addition, Simclar offers reworking and refurbishing services, which comprise redesign, rework, refurbish, and repair of materials and subassemblies; sheet metal fabrication services; and backplane interconnect solutions. The company's products are manufactured to customer specifications and designed for OEMs in the data processing, telecommunications, instrumentation, and food preparation equipment industries. The company was formerly known as Techdyne, Inc. and changed its name to Simclar, Inc. in September 2003. The company was founded in 1976 and is based in Hialeah, Florida. Simclar, Inc. operates as a subsidiary of Simclar Group Limited.
Full SIMC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.